Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ.
Gomez EB, et al. Among authors: cedervall ep.
Blood. 2023 Jul 6;142(1):62-72. doi: 10.1182/blood.2022018674.
Blood. 2023.
PMID: 36796019
Free PMC article.